Various Country Markets for Dry Eye Syndrome Drugs Analysed & Forecast by GlobalData in New Reports Now Available at MarketPublishers.com

31 Aug 2016 • by Natalie Aster

LONDON – TD The Market Publishers, Ltd. would like to inform that cutting-edge research publications, covering various world markets for dry eye syndrome (DES) drugs, prepared by GlobalData are now available in the publisher’s online catalogue at MarketPublishers.com.

Dry Eye Syndrome - 5EU Drug Forecast and Market Analysis to 2024. In the years to come the market for DES in the 5EU (France, Germany, Italy, Spain, the United Kingdom) will be driven majorly by the Santen’s launch of Ikervis, a new DES drug. As of 2014, the DES drug sales in the 5EU were estimated at USD 181 million. This in-demand research report examines the key market growth propellers and restraints, analyses the changing competitive landscape and provides future forecasts for the DES market in 5EU through 2024…

Dry Eye Syndrome - US Drug Forecast and Market Analysis to 2024. As of 2014, the DES drug sales in the USA stood at USD 1.3 billion. Since 2016, the USA DES market is likely to register stable growth. However, in 2024 the market growth is expected to slow down. An all-encompassing review of the USA DES market is provided in this comprehensive research report. The report highlights the existing treatment options, covers the top market trends, reviews key players and gives forecasts through 2024…

Dry Eye Syndrome - Japan Drug Forecast and Market Analysis to 2024. In 2014, the sales of DES drugs in Japan exceeded USD 360 million. Through 2024, the domestic DES drugs market is likely to keep on growing at a moderate steady rate. Sodium hyaluronate-based artificial tears, Santen’s Hyalein, is likely to be the top selling DES drug in Japan through 2024, in 2024 this product sales will likely exceed USD 227 million. This report is a great source of reliable information on the Japanese DES market…

Dry Eye Syndrome - India Drug Forecast and Market Analysis to 2024. Treatment and diagnosis rates are predicted to increase slightly for all severities of DES in India through 2024. Improvements in this stagnant market will likely be supported primarily by the rising disease awareness amid both physicians and patients. Nowadays, Restasis remains the only approved prescription DES drug in the Indian market. The research report provides a granular overview of the Indian DES market, contains competitive landscape analysis, gives forecasts for the India DES market…

Dry Eye Syndrome - China Drug Forecast and Market Analysis to 2024. Up to 2024, the Chinese DES market is likely to grow at a significant CAGR of 10.4%. In 2018, the Chinese DES market is predicted to outstrip the Indian market. Santen’s Hialid, a sodium hyaluronate-based artificial tears, is anticipated to be the top selling DES drug in China, with its sales reaching USD 138.5 million in 2024. This report provides an in-depth analysis of the Chinese DES market, offers updated statistics, includes an analysis of the market dynamics, highlights the latest developments and new product launches, and gives projections through 2024…

Other comprehensive research reports prepared by GlobalData are provided at its page.

CONTACTS

The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com